GlassScriptPhysician profile
Samuel Tilden
NPI 1083935357
$1,733.07
in general payments reported to CMS, 2019-2025
21 companies · $16.64 in 2025
The $16.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $268 · 2021: $193 · 2022: $366 · 2023: $167 · 2025: $16.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $220.25 | 2019-2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $213.00 | 2019-2022 | |
| Pfizer INC. | $210.89 | 2019-2022 | |
| Amgen INC. | $171.48 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $155.96 | 2019-2022 | |
| Astellas Pharma US INC | $152.98 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $122.34 | 2019-2022 | |
| Abbvie INC. | $105.79 | 2019-2023 | Vraylar |
| Abbott Laboratories | $59.65 | 2019-2022 | |
| Lilly USA, LLC | $55.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $51.39 | 2019 | |
| Medtronic, INC. | $38.51 | 2023 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.99 | 2020-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $21.74 | 2022 | |
| Inari Medical, INC. | $21.59 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $19.01 | 2023 | Senza |
| Dexcom, INC. | $16.50 | 2019 | |
| Irhythm Technologies, INC. | $16.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.50 | 2022 | |
| Promius Pharma LLC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Tilden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.